Cytotoxic Flavonoids as Agonists of Peroxisome Proliferator-Activated Receptor γ on Human Cervical and Prostate Cancer Cells

被引：16
|
作者：
Lee, Jee-Young [1 ,2 ]
Kim, Jin-Kyoung [1 ,2 ]
Cho, Min-Chul [1 ,2 ]
Shin, Soyoung [1 ,2 ]
Yoon, Do-Young [1 ,2 ]
Heo, Yong Seok [3 ]
Kim, Yangmee [1 ,2 ]
机构：
[1] Konkuk Univ, Dept Biosci & Biotechnol, Seoul 143701, South Korea
[2] Konkuk Univ, Bio Mol Informat Ctr, Seoul 143701, South Korea
[3] Konkuk Univ, Dept Chem, Seoul 143701, South Korea
来源：
JOURNAL OF NATURAL PRODUCTS | 2010年 / 73卷 / 07期
关键词：
PPAR-GAMMA; NUCLEAR RECEPTORS; FLEXIBLE DOCKING; LIGAND-BINDING; METABOLISM; ALPHA; SELECTIVITY; MINIREVIEW; DISEASE; TARGETS;
D O I：
10.1021/np100148m
中图分类号：
Q94 [植物学];
学科分类号：
071001 ;
摘要：
We conducted in silico screening for human peroxisome proliferator-activated receptor gamma (hPPAR gamma) by performing in automated docking study with 450 flavonoids. Among the eight flavonoids is possible agonises of hPPAR gamma, only 3,6-dihydroxyflavone (4) increased the binding between PPAR gamma and steroid receptor coactivator-I (SRC-I), approximately 5-fold, and showed one order higher binding affinity for PPAR gamma than a reference compound, indomethacin. The 6-hydroxy group or the A-ring of 3,6-dihydroxyflavone (4) participated in hydrogen-bonding interactions with the side chain of Tyr327, His449, and Tyr473. The B-ring formed a hydrophobic interaction with Leu330, Leu333, Val339, Ile341, and Met364. Therefore, 3,6-dihydroxyflavone is a potent agonise of hPPAR with cytotoxic effects on human cervical and prostate cancer cells.
引用
收藏
页码：1261 / 1265
页数：5
相关论文
共 50 条
  • [11] Peroxisome proliferator-activated receptor δ confers resistance to peroxisome proliferator-activated receptor γ-induced apoptosis in colorectal cancer cells
    D Wang
    W Ning
    D Xie
    L Guo
    R N DuBois
    Oncogene, 2012, 31 : 1013 - 1023
  • [12] The Cardiovascular Effects of Peroxisome Proliferator-activated Receptor Agonists
    Friedland, Sayuri N.
    Leong, Aaron
    Filion, Kristian B.
    Genest, Jacques
    Lega, Iliana C.
    Mottillo, Salvatore
    Poirier, Paul
    Reoch, Jennifer
    Eisenberg, Mark J.
    AMERICAN JOURNAL OF MEDICINE, 2012, 125 (02): : 126 - 133
  • [13] Inflammation in diabetes mellitus:: Role of peroxisome proliferator-activated receptor-α and peroxisome proliferator-activated receptor-γ agonists
    Libby, Peter
    Plutzky, Jorge
    AMERICAN JOURNAL OF CARDIOLOGY, 2007, 99 (4A): : 27B - 40B
  • [14] Eigenvalue analysis of peroxisome proliferator-activated receptor γ agonists
    Liao, CZ
    Xie, AH
    Shi, LM
    Zhou, JJ
    Lu, XP
    JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES, 2004, 44 (01): : 230 - 238
  • [15] Peroxisome proliferator-activated receptor (PPAR)γ agonists for diabetes
    Moller, DE
    Greene, DA
    ADVANCES IN PROTEIN CHEMISTRY, VOL 56: DRUG DISCOVERY AND DESIGN, 2001, 56 : 181 - +
  • [16] The Cardiovascular Effects of Peroxisome Proliferator-activated Receptor Agonists
    Kolatkar, Nikheel S.
    AMERICAN JOURNAL OF MEDICINE, 2013, 126 (03): : E11 - E11
  • [17] PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR γ AGONISTS AS NEUROPROTECTIVE AGENTS
    Kaundal, Ravinder K.
    Sharma, Shyam S.
    DRUG NEWS & PERSPECTIVES, 2010, 23 (04) : 241 - 256
  • [18] Therapeutic roles of peroxisome proliferator-activated receptor agonists
    Staels, B
    Fruchart, JC
    DIABETES, 2005, 54 (08) : 2460 - 2470
  • [19] Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists
    Grommes, C
    Landreth, GE
    Heneka, MT
    LANCET ONCOLOGY, 2004, 5 (07): : 419 - 429
  • [20] Peroxisome proliferator-activated receptor agonists, hyperlipidaemia, and atherosclerosis
    Vosper, H
    Khoudoli, GA
    Graham, TL
    Palmer, CNA
    PHARMACOLOGY & THERAPEUTICS, 2002, 95 (01) : 47 - 62
12345